Skip to main content

FDA Approvals

Drug Updates, FDA Approvals, Payers' Guide

Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Drug Updates, FDA Approvals, Payers' Guide

Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Drug Updates, FDA Approvals, Payers' Guide

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

22
23
24
25
26
27
28

Page 25 of 31
Results 241 - 250 of 305